Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Australian Technical Advisory Group on Immunization (ATAGI) has released a statement of advice for immunization providers regarding the administration of 2011 trivalent seasonal influenza vaccines.
Subscribe to our email newsletter
The ATAGI recommendations for Fluvax vaccine are consistent with the 2011 product information, which states that children under five years of age should not receive Fluvax vaccine.
In addition, ATAGI has recommended that children aged five to less than 10 years of age should receive an alternative influenza vaccine if available.
CSL Biotherapies medical director Alan Paul said CSL fully supports the ATAGI recommendations and continues to work closely with health authorities to mitigate the risk of further febrile events in children following the use of our seasonal influenza vaccine.
The ATAGI recommendations support the use of Fluvax vaccine in people aged 10 years and over.
Fluvax vaccine is the only Australian made influenza vaccine, which helps to protect Australians against influenza.